Richard Wilson Peck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Richard Wilson Peck has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Mihaela van der Schaar
University of Cambridge
3 shared publications Piet H. van der Graaf
Certara Canterbury UK
3 shared publications- Adrian P. Mander
Centre for Trials Research, Cardiff University, Cardiff, UK
2 shared publications An-Wen Chan
Department of Medicine, Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
2 shared publications- Andrew Kightley
Patient and Public Involvement and Engagement (PPIE) Lead, Lichfield, UK
2 shared publications Antoine Hommais
38Department of Clinical Research, National Cancer Institute, Boulogne-Billancourt, France
2 shared publications
Latest Publications
- Open Access
- 1 August 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (3) , 527-530
Recent Advances Addressing the Challenges of Precision Dosing
- 1 August 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (3) , 527-530
Open AccessRecent Advances Addressing the Challenges of Precision Dosing
- Open Access
- 8 February 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (3) , 602-612
Beyond Population‐Level Targets for Drug Concentrations: Precision Dosing Needs Individual‐Level Targets that Include Superior Biomarkers of Drug Responses
The purpose of precision dosing is to increase the chances of therapeutic success in individual patients. This is achieved in practice by adjusting doses to reach precision dosing targets determined previously in relevant populations, ideally with robust supportive evidence showing improved clinical outcomes compared with standard dosing. But is this implicit assumption of translatable population‐level precision dosing targets correct and the best for all patients? In this review, the types of precision dosing targets and how they are determined are outlined, problems with the translatability of these targets to individual patients are identified, and ways forward to address these challengers are proposed. Achieving improved clinical outcomes to support precision dosing over standard dosing is currently hampered by applying population‐level targets to all patients. Just as “one‐dose‐fits‐all” may be an inappropriate philosophy for drug treatment overall, a “one‐target‐fits‐all” philosophy may limit the broad clinical benefits of precision dosing. Defining individual‐level precision dosing targets may be needed for greatest therapeutic success. Superior future precision dosing targets will integrate several biomarkers that together account for the multiple sources of drug response variability.
- 8 February 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (3) , 602-612
Open AccessBeyond Population‐Level Targets for Drug Concentrations: Precision Dosing Needs Individual‐Level Targets that Include Superior Biomarkers of Drug Responses
The purpose of precision dosing is to increase the chances of therapeutic success in individual patients. This is achieved in practice by adjusting doses to reach precision dosing targets determined previously in relevant populations, ideally with robust supportive evidence showing improved clinical outcomes compared with standard dosing. But is this implicit assumption of translatable population‐level precision dosing targets correct and the best for all patients? In this review, the types of precision dosing targets and how they are determined are outlined, problems with the translatability of these targets to individual patients are identified, and ways forward to address these challengers are proposed. Achieving improved clinical outcomes to support precision dosing over standard dosing is currently hampered by applying population‐level targets to all patients. Just as “one‐dose‐fits‐all” may be an inappropriate philosophy for drug treatment overall, a “one‐target‐fits‐all” philosophy may limit the broad clinical benefits of precision dosing. Defining individual‐level precision dosing targets may be needed for greatest therapeutic success. Superior future precision dosing targets will integrate several biomarkers that together account for the multiple sources of drug response variability.
- Top Cited PapersOpen Access
- 12 January 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (4) , 710-719
Using Machine Learning to Individualize Treatment Effect Estimation: Challenges and Opportunities
The use of data from randomized clinical trials to justify treatment decisions for real‐world patients is the current state of the art. It relies on the assumption that average treatment effects from the trial can be extrapolated to patients with personal and/or disease characteristics different from those treated in the trial. Yet, because of heterogeneity of treatment effects between patients and between the trial population and real‐world patients, this assumption may not be correct for many patients. Using machine learning to estimate the expected conditional average treatment effect (CATE) in individual patients from observational data offers the potential for more accurate estimation of the expected treatment effects in each patient based on their observed characteristics. In this review, we discuss some of the challenges and opportunities for machine learning to estimate CATE, including ensuring identification assumptions are met, managing covariate shift, and learning without access to the true label of interest. We also discuss the potential applications as well as future work and collaborations needed to further improve identification and utilization of CATE estimates to increase patient benefit.
- 12 January 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (4) , 710-719
Top Cited PapersOpen AccessUsing Machine Learning to Individualize Treatment Effect Estimation: Challenges and Opportunities
The use of data from randomized clinical trials to justify treatment decisions for real‐world patients is the current state of the art. It relies on the assumption that average treatment effects from the trial can be extrapolated to patients with personal and/or disease characteristics different from those treated in the trial. Yet, because of heterogeneity of treatment effects between patients and between the trial population and real‐world patients, this assumption may not be correct for many patients. Using machine learning to estimate the expected conditional average treatment effect (CATE) in individual patients from observational data offers the potential for more accurate estimation of the expected treatment effects in each patient based on their observed characteristics. In this review, we discuss some of the challenges and opportunities for machine learning to estimate CATE, including ensuring identification assumptions are met, managing covariate shift, and learning without access to the true label of interest. We also discuss the potential applications as well as future work and collaborations needed to further improve identification and utilization of CATE estimates to increase patient benefit.
- Open Access
- 3 January 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (3) , 464-475
Development and application of neonatal physiology‐based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment
Antimicrobial resistance increasingly complicates neonatal sepsis in a global context. Fosfomycin and amikacin are two agents being tested in an ongoing multicenter neonatal sepsis trial. Although neonatal pharmacokinetics (PKs) have been described for these drugs, the physiological variability within neonatal populations makes population PKs in this group uncertain. Physiologically‐based pharmacokinetic (PBPK) models were developed in Simcyp for fosfomycin and amikacin sequentially for adult, pediatric, and neonatal populations, with visual and quantitative validation compared to observed data at each stage. Simulations were performed using the final validated neonatal models to determine drug exposures for each drug across a demographic range, with probability of target attainment (PTA) assessments. Successfully validated neonatal PBPK models were developed for both fosfomycin and amikacin. PTA analysis demonstrated high probability of target attainment for amikacin 15 mg/kg i.v. q24h and fosfomycin 100 mg/kg (in neonates aged 0–7 days) or 150 mg/kg (in neonates aged 7–28 days) i.v. q12h for Enterobacterales with fosfomycin and amikacin minimum inhibitory concentrations at the adult breakpoints. Repeat analysis in premature populations demonstrated the same result. PTA analysis for a proposed combination fosfomycin‐amikacin target was also performed. The simulated regimens, tested in a neonatal sepsis trial, are likely to be adequate for neonates across different postnatal ages and gestational age. This work demonstrates a template for determining target attainment for antimicrobials (alone or in combination) in special populations without sufficient available PK data to otherwise assess with traditional pharmacometric methods.
- 3 January 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (3) , 464-475
Open AccessDevelopment and application of neonatal physiology‐based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment
Antimicrobial resistance increasingly complicates neonatal sepsis in a global context. Fosfomycin and amikacin are two agents being tested in an ongoing multicenter neonatal sepsis trial. Although neonatal pharmacokinetics (PKs) have been described for these drugs, the physiological variability within neonatal populations makes population PKs in this group uncertain. Physiologically‐based pharmacokinetic (PBPK) models were developed in Simcyp for fosfomycin and amikacin sequentially for adult, pediatric, and neonatal populations, with visual and quantitative validation compared to observed data at each stage. Simulations were performed using the final validated neonatal models to determine drug exposures for each drug across a demographic range, with probability of target attainment (PTA) assessments. Successfully validated neonatal PBPK models were developed for both fosfomycin and amikacin. PTA analysis demonstrated high probability of target attainment for amikacin 15 mg/kg i.v. q24h and fosfomycin 100 mg/kg (in neonates aged 0–7 days) or 150 mg/kg (in neonates aged 7–28 days) i.v. q12h for Enterobacterales with fosfomycin and amikacin minimum inhibitory concentrations at the adult breakpoints. Repeat analysis in premature populations demonstrated the same result. PTA analysis for a proposed combination fosfomycin‐amikacin target was also performed. The simulated regimens, tested in a neonatal sepsis trial, are likely to be adequate for neonates across different postnatal ages and gestational age. This work demonstrates a template for determining target attainment for antimicrobials (alone or in combination) in special populations without sufficient available PK data to otherwise assess with traditional pharmacometric methods.
- 16 November 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 114 (6) , 1153-1157
Ensuring Transparency and Quality of Clinical Trial Reporting in Clinical Pharmacology & Therapeutics: Prospective Trial Registration and Compliance with Reporting Guidelines Are Required for all Clinical Trials
- 16 November 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 114 (6) , 1153-1157
Ensuring Transparency and Quality of Clinical Trial Reporting in Clinical Pharmacology & Therapeutics: Prospective Trial Registration and Compliance with Reporting Guidelines Are Required for all Clinical Trials
- Open Access
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance
SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 provides guidance for clinical trial protocol writing. However, neither the original guidance nor its extensions adequately cover the features of early phase dose-finding trials. The SPIRIT Dose-finding Extension (DEFINE) statement is a new guideline that provides recommendations for essential items that should be provided in the protocols of these trials. It details extensions to the SPIRIT 2013 guidance, incorporating 17 new items and modifying 15 existing items. The purpose of this guideline is to promote transparency, completeness, reproducibility of methods, and interpretation of early phase dose-finding trial protocols. It is envisioned that the resulting improvements in the design and conduct of early phase clinical trials will ultimately reduce research inefficiencies and inconsistencies, driving transformational advances in clinical care.
Open AccessEnhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance
SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 provides guidance for clinical trial protocol writing. However, neither the original guidance nor its extensions adequately cover the features of early phase dose-finding trials. The SPIRIT Dose-finding Extension (DEFINE) statement is a new guideline that provides recommendations for essential items that should be provided in the protocols of these trials. It details extensions to the SPIRIT 2013 guidance, incorporating 17 new items and modifying 15 existing items. The purpose of this guideline is to promote transparency, completeness, reproducibility of methods, and interpretation of early phase dose-finding trial protocols. It is envisioned that the resulting improvements in the design and conduct of early phase clinical trials will ultimately reduce research inefficiencies and inconsistencies, driving transformational advances in clinical care.
- Open Access
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance
The CONSORT (CONsolidated Standards Of Reporting Trials) 2010 statement is the standard guideline for reporting completed randomised trials. The CONSORT Dose-finding Extension (DEFINE) extends the guidance (with 21 new items and 19 modified items) to early phase dose-finding trials with interim dose escalation or de-escalation strategies. Such trials generally focus on safety, tolerability, activity, and recommending dosing and scheduling regimens for further clinical development. These trials are often inadequately reported, hampering their informativeness and making evidence informed decisions difficult. The CONSORT-DEFINE guidance aims to develop an international, consensus driven guideline for reporting early phase dose-finding trials to promote transparency, completeness, reproducibility, and facilitate the interpretation of the results. The CONSORT-DEFINE guidance provides recommendations for essential items that should be reported in early phase dose-finding trials to promote greater clarity, reproducibility, informativeness, and usefulness of results.
Open AccessEnhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance
The CONSORT (CONsolidated Standards Of Reporting Trials) 2010 statement is the standard guideline for reporting completed randomised trials. The CONSORT Dose-finding Extension (DEFINE) extends the guidance (with 21 new items and 19 modified items) to early phase dose-finding trials with interim dose escalation or de-escalation strategies. Such trials generally focus on safety, tolerability, activity, and recommending dosing and scheduling regimens for further clinical development. These trials are often inadequately reported, hampering their informativeness and making evidence informed decisions difficult. The CONSORT-DEFINE guidance aims to develop an international, consensus driven guideline for reporting early phase dose-finding trials to promote transparency, completeness, reproducibility, and facilitate the interpretation of the results. The CONSORT-DEFINE guidance provides recommendations for essential items that should be reported in early phase dose-finding trials to promote greater clarity, reproducibility, informativeness, and usefulness of results.
- 6 October 2023
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (11) , 1551-1565
Bridging the Worlds of Pharmacometrics and Machine Learning
Precision medicine requires individualized modeling of disease and drug dynamics, with machine learning-based computational techniques gaining increasing popularity. The complexity of either field, however, makes current pharmacological problems opaque to machine learning practitioners, and state-of-the-art machine learning methods inaccessible to pharmacometricians. To help bridge the two worlds, we provide an introduction to current problems and techniques in pharmacometrics that ranges from pharmacokinetic and pharmacodynamic modeling to pharmacometric simulations, model-informed precision dosing, and systems pharmacology, and review some of the machine learning approaches to address them. We hope this would facilitate collaboration between experts, with complementary strengths of principled pharmacometric modeling and flexibility of machine learning leading to synergistic effects in pharmacological applications.
- 6 October 2023
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (11) , 1551-1565
Bridging the Worlds of Pharmacometrics and Machine Learning
Precision medicine requires individualized modeling of disease and drug dynamics, with machine learning-based computational techniques gaining increasing popularity. The complexity of either field, however, makes current pharmacological problems opaque to machine learning practitioners, and state-of-the-art machine learning methods inaccessible to pharmacometricians. To help bridge the two worlds, we provide an introduction to current problems and techniques in pharmacometrics that ranges from pharmacokinetic and pharmacodynamic modeling to pharmacometric simulations, model-informed precision dosing, and systems pharmacology, and review some of the machine learning approaches to address them. We hope this would facilitate collaboration between experts, with complementary strengths of principled pharmacometric modeling and flexibility of machine learning leading to synergistic effects in pharmacological applications.
- Open Access
- 24 April 2023
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (7) , 953-962
Synthetic Model Combination: A new machine‐learning method for pharmacometric model ensembling
When aiming to make predictions over targets in the pharmacological setting, a data‐focused approach aims to learn models based on a collection of labeled examples. Unfortunately, data sharing is not always possible, and this can result in many different models trained on disparate populations, leading to the natural question of how best to use and combine them when making a new prediction. Previous work has focused on global model selection or ensembling, with the result of a single final model across the feature space. Machine‐learning models perform notoriously poorly on data outside their training domain, however, due to a problem known as covariate shift, and so we argue that when ensembling models the weightings for individual instances must reflect their respective domains—in other words, models that are more likely to have seen information on that instance should have more attention paid to them. We introduce a method for such an instance‐wise ensembling of models called Synthetic Model Combination (SMC), including a novel representation learning step for handling sparse high‐dimensional domains. We demonstrate the use of SMC on an example with dosing predictions for vancomycin, although emphasize the applicability of the method to any scenario involving the use of multiple models.
- 24 April 2023
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (7) , 953-962
Open AccessSynthetic Model Combination: A new machine‐learning method for pharmacometric model ensembling
When aiming to make predictions over targets in the pharmacological setting, a data‐focused approach aims to learn models based on a collection of labeled examples. Unfortunately, data sharing is not always possible, and this can result in many different models trained on disparate populations, leading to the natural question of how best to use and combine them when making a new prediction. Previous work has focused on global model selection or ensembling, with the result of a single final model across the feature space. Machine‐learning models perform notoriously poorly on data outside their training domain, however, due to a problem known as covariate shift, and so we argue that when ensembling models the weightings for individual instances must reflect their respective domains—in other words, models that are more likely to have seen information on that instance should have more attention paid to them. We introduce a method for such an instance‐wise ensembling of models called Synthetic Model Combination (SMC), including a novel representation learning step for handling sparse high‐dimensional domains. We demonstrate the use of SMC on an example with dosing predictions for vancomycin, although emphasize the applicability of the method to any scenario involving the use of multiple models.